Simon Cocklin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6737915/publications.pdf

Version: 2024-02-01

45 papers	1,443 citations	331670 21 h-index	345221 36 g-index
45 all docs	45 docs citations	45 times ranked	2123 citing authors

#	Article	IF	Citations
1	From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface. Chinese Chemical Letters, 2023, 34, 107611.	9.0	6
2	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. European Journal of Medicinal Chemistry, 2022, 227, 113903.	5.5	11
3	Clade-Specific Alterations within the HIV-1 Capsid Protein with Implications for Nuclear Translocation. Biomolecules, 2022, 12, 695.	4.0	3
4	Structure, Function, and Interactions of the HIV-1 Capsid Protein. Life, 2021, 11, 100.	2.4	28
5	Rapid Optimization of the Metabolic Stability of a Human Immunodeficiency Virus Type-1 Capsid Inhibitor Using a Multistep Computational Workflow. Journal of Medicinal Chemistry, 2021, 64, 3747-3766.	6.4	16
6	New RAD51 Inhibitors to Target Homologous Recombination in Human Cells. Genes, 2021, 12, 920.	2.4	22
7	Alprazolam Prompts HIV-1 Transcriptional Reactivation and Enhances CTL Response Through RUNX1 Inhibition and STAT5 Activation. Frontiers in Neurology, 2021, 12, 663793.	2.4	3
8	Subtype Differences in the Interaction of HIV-1 Matrix with Calmodulin: Implications for Biological Functions. Biomolecules, 2021, 11, 1294.	4.0	1
9	Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. Bioorganic and Medicinal Chemistry, 2021, 48, 116414.	3.0	4
10	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. European Journal of Medicinal Chemistry, 2021, 226, 113848.	5.5	15
11	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Journal of Medicinal Chemistry, 2020, 63, 12256-12274.	6.4	183
12	Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability. Molecules, 2020, 25, 1430.	3.8	11
13	Bioisosteric Replacement as a Tool in Anti-HIV Drug Design. Pharmaceuticals, 2020, 13, 36.	3.8	35
14	Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. European Journal of Medicinal Chemistry, 2020, 190, 112085.	5.5	65
15	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Journal of Medicinal Chemistry, 2020, 63, 4790-4810.	6.4	41
16	Recent Advances in HIV-1 Gag Inhibitor Design and Development. Molecules, 2020, 25, 1687.	3.8	16
17	Kinetic Characterization of Novel HIV-1 Entry Inhibitors: Discovery of a Relationship between Off-Rate and Potency. Proceedings (mdpi), 2019, 22, 77.	0.2	0
18	Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor. Molecules, 2019, 24, 1581.	3.8	8

#	Article	IF	Citations
19	Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. RSC Advances, 2019, 9, 28961-28986.	3.6	42
20	Kinetic Characterization of Novel HIV-1 Entry Inhibitors: Discovery of a Relationship between Off-Rate and Potency. Molecules, 2018, 23, 1940.	3.8	8
21	Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. European Journal of Medicinal Chemistry, 2018, 158, 478-492.	5.5	51
22	Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action. , 2018, 5, .		21
23	Interaction between the AAA+ ATPase p97 and its cofactor ataxin3 in health and disease: Nucleotide-induced conformational changes regulate cofactor binding. Journal of Biological Chemistry, 2017, 292, 18392-18407.	3.4	25
24	The spliceosomal proteins PPIH and PRPF4 exhibit bi-partite binding. Biochemical Journal, 2017, 474, 3689-3704.	3.7	4
25	Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Research, 2016, 44, 4189-4199.	14.5	81
26	IgG Binding Characteristics of Rhesus Macaque FcÎ³R. Journal of Immunology, 2016, 197, 2936-2947.	0.8	43
27	Insertion of perilipin 3 into a glycero(phospho)lipid monolayer depends on lipid headgroup and acyl chain species. Journal of Lipid Research, 2016, 57, 1465-1476.	4.2	23
28	Phosphorylation of the RNA-binding protein Dazl by MAPKAP kinase 2 regulates spermatogenesis. Molecular Biology of the Cell, 2016, 27, 2341-2350.	2.1	17
29	Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 228-234.	2.2	19
30	Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 824-828.	2.2	20
31	Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5439-5445.	2.2	25
32	The high resolution structure of tyrocidine A reveals an amphipathic dimer. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1199-1207.	2.6	36
33	Structureâ€“Activity Relationships of a Novel Capsid Targeted Inhibitor of HIV-1 Replication. Journal of Chemical Information and Modeling, 2014, 54, 3080-3090.	5.4	22
34	An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody ResponsesIn Vivo. Infection and Immunity, 2014, 82, 4080-4091.	2.2	31
35	Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1132-1135.	2.2	30
36	Identification of a Smallâ€Molecule Inhibitor of HIVâ€1 Assembly that Targets the Phosphatidylinositol (4,5)â€bisphosphate Binding Site of the HIVâ€1 Matrix Protein. ChemMedChem, 2013, 8, 426-432.	3.2	34

#	Article	IF	Citations
37	Inhibiting Early-Stage Events in HIV-1 Replication by Small-Molecule Targeting of the HIV-1 Capsid. Journal of Virology, 2012, 86, 8472-8481.	3.4	73
38	Inhibition of Homologous Recombination in Human Cells by Targeting RAD51 Recombinase. Journal of Medicinal Chemistry, 2012, 55, 3011-3020.	6.4	115
39	Introducing metallocene into a triazole peptide conjugate reduces its offâ€rate and enhances its affinity and antiviral potency for HIVâ€1 gp120. Journal of Molecular Recognition, 2009, 22, 169-174.	2.1	41
40	Structural Determinants for Affinity Enhancement of a Dual Antagonist Peptide Entry Inhibitor of Human Immunodeficiency Virus Type-1. Journal of Medicinal Chemistry, 2008, 51, 2638-2647.	6.4	45
41	The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology, 2008, 5, 89.	2.0	42
42	Broad-Spectrum Anti-Human Immunodeficiency Virus (HIV) Potential of a Peptide HIV Type 1 Entry Inhibitor. Journal of Virology, 2007, 81, 3645-3648.	3.4	42
43	Real-time monitoring of the membrane-binding and insertion properties of the cholesterol-dependent cytolysin anthrolysin O fromBacillus anthracis. Journal of Molecular Recognition, 2006, 19, 354-362.	2.1	16
44	Interaction with CD4 and Antibodies to CD4-Induced Epitopes of the Envelope gp120 from a Microglial Cell-Adapted Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology, 2005, 79, 6703-6713.	3.4	18
45	Mode of Action for Linear Peptide Inhibitors of HIV-1 gp120 Interactions. Biochemistry, 2004, 43, 1928-1938.	2.5	51